Anti-Hu CD13 PE-Cy™7

Anti-Hu CD13 PE-Cy™7
Regulatory status
RUO
Antigen
CD13
Clone
WM15
Format
PE-Cy™7
Reactivity
Human, Non-human primates
Application
Excitation laser
blue (488 nm)
Variant
100 tests
T7-396-T100
In stock
275.00 USD
Variant
100 tests
T7-396-T100
In stock
275.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1
Specificity
The antibody WM15 recognises an extracellular epitope of human CD13 cell surface glycoprotein, a 150 kDa molecule expressed on granulocytes, endothelial cells, epithelial cells and myeloid progenitors.
Workshop
HLDA III: WS Code M 213; HLDA IV: WS Code M 44; HLDA IV: WS Code M 209; HLDA V: WS Code M MA191
Application
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Human, Non-human primates
Immunogen
Human AML cells
Preparation
Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-cyanine 7 (PE-Cy™7) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Licence note
Cy™ and CyDye™ are registered trademarks of Cytiva.
Other names
Aminopeptidase N, APN, PEPN, ANPEP, gp150, LAP1
Antigen description
CD13 (aminopeptidase N, APN) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides, thus activating or inactivating bioactive peptides. CD13 has also role in extracellular matrix degradation, antigen processing and signal transduction, is important in inflammatory responses, regulates intercellular contact, cell motility and vascularization. CD13 is involved in protection of leukemic cells against apoptosis and its expression associated with poor prognosis of carcinomas.
Entrez Gene ID 290
UniProt ID P15144
T7-396_FC_Profil značení
Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD13 (WM15) PE-Cy™7 antibody (4 μl reagent / 100 μl of peripheral whole blood).
T7-396_FC_Histogram
Separation of human CD13 positive neutrophil granulocytes (red-filled) from lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD13 (WM15) PE-Cy™7 antibody (4 μl reagent / 100 μl of peripheral whole blood).

General references:

Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006 Jul 1;12(13):3971-8.
PubMed
Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH. CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007 Jul 1;110(1):142-50.
PubMed
Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007 Jul 27;7:140.
PubMed

Product specific references:

Favaloro EJ, Browning T, Facey D: CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp Hematol. 1993 Dec;21(13):1695-701.
PubMed
McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555.
PubMed
Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
Leukocyte Typing III., McMichael A.J. et al. (Eds.), Oxford University Press (1987).
Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E: Myeloid progenitor surface antigen identified by monoclonal antibody. Br J Haematol. 1985 Sep;61(1):11-20.
PubMed
Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Berndt MC, Musgrove E: Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. Pathology. 1985 Jul;17(3):392-9.
PubMed
Variant
100 tests
T7-396-T100
In stock
275.00 USD
Variant
100 tests
T7-396-T100
In stock
275.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
ApplicationFC, FC(IC)
0.1 mg
253.00 USD